160 related articles for article (PubMed ID: 24216569)
21. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
22. The case of the vicious virus.
Eisenberg S
ONS Connect; 2012 Nov; 27(11):19. PubMed ID: 23316523
[No Abstract] [Full Text] [Related]
23. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
24. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
25. Primary tuberculous peritonitis during infliximab therapy for Crohn's disease.
Bonse-Geuking U; Kraus M
J Crohns Colitis; 2012 Jul; 6(6):720-3. PubMed ID: 22398070
[TBL] [Abstract][Full Text] [Related]
26. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
Joosten AA; van Olffen GH; Hageman G
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.
Lin Z; Bai Y; Zheng P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1100-10. PubMed ID: 21971373
[TBL] [Abstract][Full Text] [Related]
28. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
29. An uncommon cause of abdominal pain and fever in a patient with Crohn's disease.
Wysocki JD; Said SM; Papadakis KA
Gastroenterology; 2015 May; 148(5):e12-3. PubMed ID: 25824348
[No Abstract] [Full Text] [Related]
30. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
31. Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.
Côté-Daigneault J; Peerani F; MacMahon E; Delaporte E; Rahier JF; Colombel JF
Inflamm Bowel Dis; 2016 Oct; 22(10):2538-47. PubMed ID: 27598743
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
33. A patient with haemorrhagic bullae. Varicella zoster virus (VZV).
Westdorp H; Sinnige HA
Neth J Med; 2012 May; 70(4):189, 195. PubMed ID: 22641631
[No Abstract] [Full Text] [Related]
34. Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy.
Dahhan T; Al Kahtani K; Bakshi N; Abouzied ME; Helmy A
Trop Gastroenterol; 2010; 31(1):51-3. PubMed ID: 20860231
[No Abstract] [Full Text] [Related]
35. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
36. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
[TBL] [Abstract][Full Text] [Related]
37. Development of miliary tuberculosis under infliximab in a patient with spondyloarthritis and suspected Crohn's disease.
Koschny R; Junghanss T; Mischnik A; Karner M; Kreuter M; Roth W; Stremmel W; Merle U
Z Gastroenterol; 2013 Oct; 51(10):1177-83. PubMed ID: 24122379
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case.
Ishiguro A; Takama H; Yanagishita T; Ohshima Y; Watanabe D
J Dermatol; 2019 Aug; 46(8):e270-e271. PubMed ID: 30897230
[No Abstract] [Full Text] [Related]
39. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
40. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
